Study of AGEN1884 With Pembrolizumab in 1L NSCLC

NCT03411473 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

2

Enrollment

INDUSTRY

Sponsor class

Stopped Trial will not proceed due to changes in the treatment landscape.

Conditions

NSCLC Stage IV

Interventions

BIOLOGICAL: AGEN1884 in combination with pembrolizumab

Sponsor

Agenus Inc.